Buy Semaglutide 10mg: GLP-1 Receptor Agonist for Diabetes & Weight Research

Semaglutide (10mg) is a synthetic long-acting GLP-1 receptor agonist widely studied for its effects on type 2 diabetes and obesity. Research, including landmark SUSTAIN and STEP trials, highlights its role in improving insulin sensitivity, regulating appetite, supporting substantial weight loss, and offering potential cardiovascular benefits. This research-grade peptide, supplied in a 10mg vial with 99% purity, is ideal for investigating incretin pathways, glycemic control, satiety signaling, lipolysis, and metabolic outcomes in experimental models.

Molecular Formula: C187H291N45O59 Molecular Weight: 4113.6–4114 g/mol Purity: 99%

Important Notice: This peptide is strictly intended for research and laboratory use only. Not for human consumption, diagnostic, therapeutic, or veterinary purposes. Please review and agree to our Terms and Conditions before placing an order.

What is Semaglutide?

Semaglutide is a 31-amino-acid polypeptide analog of glucagon-like peptide-1 (GLP-1), modified with an Aib8 substitution, Arg34 replacement, and a C18 fatty diacid chain linked via a γGlu-2xOEG spacer at Lys26 for prolonged half-life (~1 week) and enhanced albumin binding. These structural changes enable once-weekly dosing analogs in research while retaining potent GLP-1 receptor activation.

In clinical and preclinical studies, semaglutide has shown superior HbA1c reductions and weight loss compared to placebo or other GLP-1 agonists, with sustained effects on body composition and cardiometabolic risk factors.

The 10mg vial supports flexible reconstitution for mid-range dosing simulations, pharmacokinetics, chronic exposure models, or comparative incretin studies.

Mechanism of Action

Semaglutide mimics GLP-1 to:

• Stimulate glucose-dependent insulin secretion from pancreatic beta cells
• Suppress glucagon release in a glucose-dependent manner
• Slow gastric emptying and promote satiety
• Reduce central appetite signals and caloric intake
• Improve insulin sensitivity and beta-cell function

This incretin-based action lowers fasting and postprandial glucose while driving significant fat mass reduction, particularly visceral adipose tissue.

Key Research Findings and Benefits

Semaglutide excels in metabolic and obesity-related investigations.

Glycemic Control in Type 2 Diabetes Models

SUSTAIN trials demonstrated HbA1c reductions of ~1.5–1.8% at higher doses, with many participants achieving targets below 7% or normoglycemic levels.

Weight Loss and Obesity Management

STEP trials showed average reductions of ~12–15% body weight over 68 weeks at top doses, with substantial proportions achieving ≥15–20% loss. Benefits include sustained fat loss and improved body composition.

Cardiovascular and Metabolic Support

Studies indicate favorable changes in blood pressure, lipid profiles (reduced triglycerides/LDL), and potential risk reduction for major adverse cardiovascular events in high-risk models.

Research Applications

The 10mg format supports:

• Type 2 diabetes pathway and adjunct therapy studies
• Obesity and overweight experimental models
• Appetite regulation, gastric motility, and satiety mechanism research
• Incretin biology, metabolic syndrome, and long-term exposure investigations

Reconstitution example (lab protocols vary): Dissolve in bacteriostatic water for concentrations enabling weekly dosing analogs from initiation to maintenance levels.

Why Choose 99% Pure Semaglutide 10mg?

Our semaglutide 10mg offers ≥99% purity for reliable, reproducible results in receptor activation, insulin dynamics, and metabolic endpoint studies. Vacuum-sealed and third-party tested to minimize variables.

In summary, Semaglutide 10mg is a versatile, high-quality GLP-1 agonist for advanced research into type 2 diabetes management, weight loss, appetite regulation, insulin sensitivity, and cardiometabolic health. Explore its incretin potential in your laboratory studies today.

Latest Testing: Link to Report